NCT00973934|CompletedPhase 2DMC
Magnetic Seizure Therapy (MST) for the Treatment of Major Depression
MST-2
Loading search results
MST-2
Sponsor study identifier
Secondary identifiers
interventional
20
1 country
2
Study Start
April 2002
Date type not reportedThis date has not been verified as actual or estimated.
Primary Completion
January 2006
Actual (reported)Study Completion
December 2009
Actual (reported)This two-center, between-subject, randomized, double-masked study (n=20) will provide the first evidence for the antidepressant efficacy of Magnetic Seizure Therapy (MST) and contrast the therapeutic properties and side effects of two forms of MST in patients in a major depressive episode (MDE).
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
December 2009
Actual (reported)Click on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
April 2002
Date type not reportedThis date has not been verified as actual or estimated.
January 2006
Actual (reported)September 4, 2009
Actual (reported)September 9, 2009
Actual (reported)December 2009
Actual (reported)Hamilton Rating Scale for Depression (HRSD), 24 item
A blinded rater will administer the test at Baseline, every Tuesday and Thursday during the treatment course and at the end of the MST course
Beck Depression Inventory
A blinded rater will administer the test at Baseline, every Tuesday and Thursady during the treatment course and at the end of the MST course
Neuropsychological testings to assess the acute, short term, long term memory effects of the treatments
A blinded rater will administer various neurospychologiocal tests at various timepoints (baseline, within 3 days following the MST course and at 2 months following the MST course. Treatment Effect Battery (TEB) will be administered at each MST session.
Eligible patients will be randomized to receive either a course of thrice weekly MST using either a focal or non focal stimulating coil.
Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
Duke Universtiy Medical Center
Durham, North Carolina, 27710, United States
University of Texas Southwestern Medical Center
Dallas, Texas, 75390, United States
Jiang J, Zhang C, Li C, Chen Z, Cao X, Wang H, Li W, Wang J. Magnetic seizure therapy for treatment-resistant depression. Cochrane Database Syst Rev. 2021 Jun 16;6(6):CD013528. doi: 10.1002/14651858.CD013528.pub2.
20 participants (actual enrollment reported by the registry).
First Submitted
September 4, 2009
First Posted
September 9, 2009
Study Start
April 2002
Date type not reportedThis date has not been verified as actual or estimated.
The Antidepressant Effects Of The NMDA Antagonist, CP-101,606, In Patients With MDD
Contact the study team to confirm eligibility.
Primary Completion
January 2006
Actual (reported)Study Completion
December 2009
Actual (reported)Last Updated
June 10, 2014
Record last verified: 2014-06
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: